Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis

Table 1 Characteristics of the included studies

Ref.	Publication(yr)	Study periods(yr)	Region	Arms	Samplesize	Population3	Recipient age	Donor age	UrgentIndications34	Donor type3	Prescription for ABO-I LT	Immunosuppression
Song et al[28]	2016	2008-2013	South Korea	ABO-I	235	Adult	52.8 ± 8.0	29.2 ± 9.1	No	Living	Rituximab, PE, GLI (±), Splenectomy (±), Cyclophosphamide	Steroids, Basiliximab,Tac, MMF
				ABO-C	1301		51.7 ± 5.9	28.2 ± 7.6
Kim et al[29]	2016	2010-2013	South Korea	ABO-I	472	Adult	50 (22-65)	32 (18-68)	No	Living	Rituximab, PE, GLI (±)	Steroids, Basiliximab, Tac, MMF
				ABO-C	942		51 (20-68)	30 (18-62)
Kim et al[30]	2016	2011-2014	South Korea	ABO-I	252	Adult	51.3 ± 6.7	30.1 ± 11.2	No	Living	Rituximab, PE, IVIG, Preoperative MMF	Steroids, Basiliximab, Tac, MMF
				ABO-C	752		51.1 ± 6.7	28.8 ± 11.3
Ikegami et al[31]	2016	1997-2013	Japan	ABO-I	19	Adult	47.7 ± 15.7	36.6 ± 11.3	No	Living	Rituximab3, IVIG (±), PE, GLI (±), Splenectomy (±), Preoperative MMF (±)	Steroids, Tac (or CsA), MMF
				ABO-C	389		51.7 ± 11.9	37.4 ± 10.5
Lee et al[32]	2015	2006-2013	Taiwan	ABO-I	46	Adult	53.5 (19-67)	NA	No	Living	Rituximab, Plasmapheresis (or PE)	Steroids, Tac, MMF
				ABO-C	340		54.7 (18-70)	NA
Shen et al[33]	2014	2010-2013	China	ABO-I	35	Adult	46.7 ± 12.1	NA	Yes	Deceased	Rituximab, IVIG	Steroids, Basiliximab, Tac, MMF
				ABO-C	66		42.6 ± 10.2	NA
Heffron et al[34]	2010	1998-2008	United States	ABO-I	12	Pediatric	NA	NA	Yes	Deceased	-	Steroids, Daclizumab, Tac, MMF
				ABO-C	21		NA	NA
Stewart et al[35]	2009	1990-2006	United States	ABO-I	1302	Infant	0.3	8.1	No	Deceased	NA	NA
				ABO-C	3902		0.4	8.3
				ABO-I	1162	Pediatric	9.6	23.9
				ABO-C	3482		9	16.5
				ABO-I	5852	Adult	45.7	36
				ABO-C	17552		50.3	37.9
Iwamoto et al[36]	2008	2000-2007	Japan	ABO-I	15	Adult	NA	NA	No	Living	NA	NA
				ABO-C	37		NA	NA
Toso et al[20]	2007	1991-2005	Canada	ABO-I	14	Adult	42 (17-61)	NA	Yes	Deceased	Lymphocyte-depleting antibodies5, Plasmapheresis (±)	Steroids, Daclizumab, CsA (or Tac), AZA (or MMF, Sirolimus)
				ABO-C1	29		47 (16-62)	NA
				ABO-Id	65		47 (17-66)	NA
Saito et al[37]	2007	2000-2001	Japan	ABO-I	10	All ages	NA	NA	No	Deceased,	NA	NA
				ABO-C	81		NA	NA		Living
Koukoutsis et al[19]	2007	1984-2005	United Kingdom	ABO-I	4	Adult	NA	NA	Yes	Deceased	NA	NA
				ABO-C1	73		NA	NA
				ABO-Id	203		NA	NA
Ueda et al[18]	2006	1990-2003	Japan	ABO-I	74	Pediatric	NA	NA	No	Living	Steroids pulse weekly, PGE1, CsA - > AZA (1 mo after LT)	Steroids, Tac
				ABO-C1	114		NA	NA
				ABO-Id	380		NA	NA
Heffron et al[38]	2006	1999-2005	United States	ABO-I	16	Pediatric	6.5 ± 6.2	NA	No	Deceased	Plasmapheresis (±)	Steroids, Daclizumab, Tac, MMF
				ABO-C	122		8.1 ± 6.2	NA
Bjøro et al[17]	2003	1990-2001	Nordic countries	ABO-I	10	All ages	NA	44.8 (22-55)	Yes	Deceased	NA	NA
				ABO-C†	76		NA	42.3 (12-85)
				ABO-Id	143		NA	41.0 (2-75)
Chui et al[39]	1997	1986-1996	Australia	ABO-I	7	All ages	13 (6-32)	NA	Yes	Deceased	Plasmapheresis (±), Splenectomy (±)	Steroids, CsA, AZA
				ABO-C	36		NA	NA
Cacciarelli et al[16]	1995	1988-1993	United States	ABO-I	14	Pediatric	2.2 ± 1.1	NA	No	Deceased	OKT3 (or ATG, CsA)	Steroids, ATG (or OKT3, CsA), Tac
				ABO-C†	22		4.2 ± 1.0	NA
				ABO-Id	108		3.7 ± 0.5	NA
Lo et al[40]	1994	1988-1993	United States	ABO-I	29	All ages	NA	NA	Yes	Deceased	ATG (±)	Steroids, CsA (or OKT3), AZA
				ABO-C	196		NA	NA
Sanchez et al[41]	1993	1985-1991	United States	ABO-I	182	Adult	45 (16-61)	NA	No	Deceased	NA	NA
				ABO-C	182		47 (17-59)	NA
Reding et al[15]	1992	1984-1989	Belgium	ABO-I	16	All ages	NA	NA	Yes	Deceased	OKT3 (±)	Steroids, CsA, AZA(±)
				ABO-C†	16		NA	NA
				ABO-Id	38		NA	NA
Gugenheim et al[5]	1990	1984-1988	France	ABO-I	17	All ages	30 (12-49)	NA	Yes	Deceased	-	Steroids, CsA, AZA
				ABO-C	217		NA	NA

¹Compatible, but not identical; ²Propensity or case matched patients;

³If there are minority groups that make up less than about 10%, the article is categorized as covering the majority;

⁴Such as FHF, ALF, retransplantation, and critically ill patients in the intensive care unit; ⁵Documented as "lymphocyte-depleting antibodies", but not clarified exactly. ABO-C: ABO-compatible; ABO-I: ABO-incompatible; ABO-Id: ABO-identical; ATG: anti-thymocyte globulin; AZA: Azathioprine; CsA: Cyclosporin A; GLI: Graft local infusion; IVIG: Intravenous immunoglobulin; LT: Liver transplantation; MMF: Mycophenolate mofetil; NA: Not applicable; OKT3: Muromonab-CD3; PE: Plasma exchange; Tac: Tacrolimus.